Stay updated on Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page
- Check3 days agoChange DetectedRevision metadata updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check11 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedAdded a site revision note (Revision: v3.4.2) and removed the previous funding-status notice and prior revision (v3.4.1). These are administrative changes to the site rather than changes to the study content.SummaryDifference0.5%

- Check46 days agoChange DetectedAdded a government funding notice and updated the revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.4%

- Check53 days agoChange DetectedAdded a Show glossary option and minor capitalization/wording updates to UI metadata (such as QC criteria label and version text). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check60 days agoChange DetectedMinor formatting and UI adjustments observed; core study details such as inclusion criteria, outcomes, and enrollment appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.